Stock 688089 CABIO BIOTECH (WUHAN) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cabio Biotech (Wuhan) Co., Ltd.

Equities

688089

CNE100005X31

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-22 EDT 		5-day change 1st Jan Change
15.98 CNY -2.86% Intraday chart for Cabio Biotech (Wuhan) Co., Ltd. -6.00% -10.73%
04-30 Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises RE
04-26 Cabio Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Food Processing

1st Jan change Capi. Investor Rating ESG Refinitiv
CABIO BIOTECH (WUHAN) CO., LTD. Stock Cabio Biotech (Wuhan) Co., Ltd.
-10.73% 382M -
ZHEJIANG NHU COMPANY LTD. Stock Zhejiang NHU Company Ltd.
+15.09% 8.35B
D+
BELLRING BRANDS, INC. Stock BellRing Brands, Inc.
+3.37% 7.62B
C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD. Stock CSPC Innovation Pharmaceutical Co., Ltd.
+1.45% 6.01B -
THE SIMPLY GOOD FOODS COMPANY Stock The Simply Good Foods Company
-6.26% 3.75B
B-
BYHEALTH CO., LTD Stock Byhealth Co., Ltd
-9.86% 3.7B
D
XIAMEN KINGDOMWAY GROUP COMPANY Stock Xiamen Kingdomway Group Company
-6.55% 1.34B - -
HERBALIFE LTD. Stock Herbalife Ltd.
-28.83% 1.13B
B+
SIRIO PHARMA CO., LTD. Stock Sirio Pharma Co., Ltd.
+14.31% 992M -
USANA HEALTH SCIENCES, INC. Stock USANA Health Sciences, Inc.
-10.78% 925M
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. 688089 Stock
  4. Ratings Cabio Biotech (Wuhan) Co., Ltd.